About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retinal diseases, including neovascular (wet) age-related macular degeneration (nAMD).
In the United States, LYTENAVA (bevacizumab-vikg) injection is the first and only FDA-approved ophthalmic bevacizumab formulation for the treatment of nAMD (wet AMD).
LYTENAVA (bevacizumab gamma) is also authorized for the treatment of nAMD (wet AMD) in the European Union by the European Commission and in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA).
About LYTENAVA
LYTENAVA is a recombinant humanized IgG1 monoclonal antibody specific for human vascular endothelial growth factor (VEGF). Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.
